AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05469854
Drug: Linaprazan glurate
RxNorm normalized name: calcium glucarate
DrugBank: Calcium saccharate (DB13962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaprazan glurate base formulation, 25 mg oral tablets (300 mg and 600 mg doses).~Linaprazan glurate hydrochloride (HCl), 25 mg and 100 mg (as base) oral tablets (200 mg and final dose level of maximum 400 mg).
Trial: NCT05559580
Drug: Avenciguat (BI 685509)
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509)
Trial: NCT06150144
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.
Trial: NCT06390410
Drug: Simufilam
RxNorm normalized name: Simufilam
DrugBank: Simufilam (DB18817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PTI-125
Trial: NCT04598230
Drug: Combination therapy (COMB)
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this arm will receive cognitive behavioral therapy comparable to that in the cognitive behavioral therapy arm, plus one of three selective serotonin reuptake inhibitors (SSRI) medications (fluoxetine, sertraline, escitalopram)
Trial: NCT06736574
Drug: Omecamtiv Mecarbil (OM)
RxNorm normalized name: Sudafed OM
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06777303
Drug: curcurmin loaded on chitosan nano-particles
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
Trial: NCT06777303
Drug: hyaluronic acid loaded on chitosan nano-particles
RxNorm normalized name: Chitosan
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
Trial: NCT06777303
Drug: chitosan nano-particles
RxNorm normalized name: Chitosan
DrugBank: Chitosan low molecular weight (20-200 mpa.s) (DB14155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the +ve control group in the study
Trial: NCT06782646
Drug: Berberine
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take purified berberine (500 mg orally twice a day) for 12 weeks.
Trial: NCT06158854
Drug: ABBV-383 (Etentamig)
RxNorm normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT04477317
Drug: 4% Articaine Hydrochloride with 1:100,000 Adrenaline
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: new Egyptian articane anesthetic solution.
Trial: NCT04477317
Drug: 2% Mepivacaine Hydrochloride with 1:20,000 Levonordefrin
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mepecaine-L is the brand name of the Egyptian 2% Mepivacaine. It is the most commonly used anesthetic solution in Egypt due to its availability and its lower cost.
Trial: NCT04761627
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive subcutaneous (SC) injection of ustekinumab.
Trial: NCT04761627
Drug: ABP 654
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of ABP 654.
Trial: NCT04650087
Drug: Apixaban 2.5 MG
RxNorm normalized name: apixaban 2.5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will take Apixaban 2.5 MG twice a day, once in the morning and once in the evening for 30 days. Participants will be contacted (electronic or telephone) 2 days after starting the study medication and will continue up to day 90 after starting study treatment. Followup will occur from the time of discharge through the 30 day study period with contacts at 2 days, 10 days, 20 days and 30 days after discharge. Two additional study contacts will take place 45 days and 90 days after discharge.
Trial: NCT04718675
Drug: KB-0742
RxNorm normalized name: NF-KB Decoy
DrugBank: NF-kappaB Decoy (DB05559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT06703476
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient will receive alvimopan as a fixed 12-mg dose, with the first dose administered 0.5 to 5 h before the start of surgery; administration will be continued with twice daily oral doses postoperatively until hospital discharge or a maximum of 7 days (15 in-hospital doses).
Trial: NCT05172245
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05172245
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05243342
Drug: XmAb24306
RxNorm normalized name: XmAb24306
DrugBank: XmAb24306 (DB17526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XmAb24306 will be given via intravenous (IV) infusion
Trial: NCT05243342
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
Trial: NCT06058299
Drug: TBAJ-876
RxNorm normalized name: TBAJ-876
DrugBank: TBAJ-876 (DB18807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT06058299
Drug: Pretomanid
RxNorm normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg
Trial: NCT06058299
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg
Trial: NCT06058299
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg for 8 weeks followed by 100 mg for 18 weeks
Trial: NCT06058299
Drug: HRZE
RxNorm normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight
Trial: NCT06058299
Drug: HR
RxNorm normalized name: Thr
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
Trial: NCT06193863
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At the discretion of the treating physician, based on the recommendations written in the local product information.
Trial: NCT05207085
Drug: Valbenazine Oral Capsule
RxNorm normalized name: valbenazine Oral Capsule
DrugBank: Valbenazine (DB11915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
Trial: NCT06301256
Drug: TIRZEPATIDE
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tirzepatide injection contains tirzepatide, a once weekly dual receptor, GIP and GLP-1 receptor agonis t. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68.
Trial: NCT06106828
Drug: Satralizumab
RxNorm normalized name: SATRALIZUMAB
DrugBank: Satralizumab (DB15762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Satralizumab will be administered by SC injection.
Trial: NCT06054477
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg Q3W
Trial: NCT05195944
Drug: Semaglutide Treatment
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The participants will be provided with Semaglutide, titrated up to 14 mg. The starting dose of Semaglutide is 3 mg once daily. At week 4, the dose will be increased to 7 mg once daily. At week 8, the dose will be increased to 14 mg once daily and will be maintained at 14mg until End of Treatment (week 26). Throughout the 26 week treatment period, participants in this arm will also take one sitagliptin placebo tablet per day.
Trial: NCT05195944
Drug: Sitagliptin 100mg
RxNorm normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: participants will take 100mg tablet of Sitagliptin once daily, along with a semaglutide placebo pill for the duration of the 26 week treatment period
Trial: NCT05501483
Drug: Pioglitazone 45 mg
RxNorm normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starts with 45 mg
Trial: NCT05501483
Drug: Empagliflozin 25 MG
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starts with 25 mg
Trial: NCT05501483
Drug: Semaglutide 7 MG
RxNorm normalized name: semaglutide 7 MG
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starts with 3 mg daily for the first 2 weeks
Trial: NCT05843253
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib PO qd on days 1-21
Trial: NCT05843253
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus PO qd on days 1-28
Trial: NCT06465953
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Trial: NCT06465953
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Trial: NCT04741542
Drug: SP-420
RxNorm normalized name: SP-420
DrugBank: SP-420 (DB16069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Trial: NCT05047783
Drug: Masitinib Mesylate
RxNorm normalized name: Axitinib
DrugBank: Masitinib (DB11526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3CL-protease inhibitor
Trial: NCT05847517
Drug: Metoprolol Injection
RxNorm normalized name: metoprolol Injection
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dilution of 15 mg Metoprolol tartrate in 100 ml saline shall be performed and infused for 10 minutes. No dose reduction or increase is allowed. Systolic blood pressure and heart rate shall be measured 3 and 6 minutes after starting the infusion.~In case of a consistent drop in systolic blood pressure or heart rate, the infusion shall be stopped and the infusion noted.
Trial: NCT06478719
Drug: FB-1603
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB-1603 (165 mg/cap) oral capsule
Trial: NCT04890041
Drug: TPO-RA
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive an initial dose of TPO-RA once daily. Platelet counts were collected weekly until week 6 of the study. Dosage was adjusted to maintain platelet levels between 50×10\^9/L and 150×10\^9/L according to platelet count. TPO-RA was administered once a day for 4 weeks. If the platelet count dose not reach 30×10\^9/L, the treatment was stopped. If the platelet count is more than 400×10\^9/L after taking TPO-RA once a day for 2 consecutive weeks, the treatment will be stopped.
Trial: NCT05737628
Drug: BYON4228 + Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses.~Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles.
Trial: NCT06280092
Drug: AMSCs
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery
Trial: NCT05789602
Drug: BPI-460372
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive BPI-460372 until disease progression
Trial: NCT05273320
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nabilone capsules at a maximum dose of 1 mg twice a day
Trial: NCT05424549
Drug: Reproxalap Ophthalmic Solution (0.25%)
RxNorm normalized name: Reproxalap
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproxalap Ophthalmic Solution (0.25%) dosed six times over two consecutive days
Trial: NCT05424549
Drug: Vehicle Ophthalmic Solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Ophthalmic Solution dosed six times over two consecutive days
Trial: NCT04985396
Drug: Platelet Rich Plasma (PRP) group
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet Rich Plasma (PRP) group will be intervened with PRP injection. The collection of 30 ml blood of patients into acid citrate dextrose tube under aseptic condition will be done and subjected for centrifugation at 2000 rpm (soft spin) through digital centrifuge machine speed control (REMI, R-8C PLUS). There will be three layers of blood, among them the supernatant layer and buff coat of plasma will be again subjected to centrifuge at 3000 rpm (hard spin). The upper two thirds of the tube containing platelet poor plasma will be discarded and finally, the lower one third concentrated platelet plasma superficial buffy coat will be injected into medial calcaneal tuberosity at the most tender point.
Trial: NCT06064500
Drug: Tarlatamab
RxNorm normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab will be administered as a 60-minute intravenous infusion with 1 mg step dose on cycle 1 day 1 followed by a 10 mg target dose on cycle 1 day 8 and cycle 1 day 15 in a 28-day cycle. Subsequent doses (10 mg) will be administered every 2 weeks.
Trial: NCT04572763
Drug: Copanlisib
RxNorm normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04572763
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet taken orally
Trial: NCT05592418
Drug: Rintatolimod
RxNorm normalized name: Rintatolimod
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 to 400 mg twice weekly
Trial: NCT05089448
Drug: Alisartan, Amlodipine besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs will be taken once daily at 6:00-10:00.
Trial: NCT05089448
Drug: Alisartan, Amlodipine besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drugs will be taken once daily at 20:00-24:00.
Trial: NCT04509102
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Adderall XR will initiate treatment with 15 mg daily (one 15 mg tablet each morning) for 21 days.
Trial: NCT06010329
Drug: Sutetinib Maleate Capsule
RxNorm normalized name: chlorpheniramine maleate Oral Capsule
DrugBank: Sutetinib (DB18841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04855747
Drug: REL-1017
RxNorm normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REL-1017 tablet
Trial: NCT05477407
Drug: Switch from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will be evaluated with an adipose tissue biopsy performed before (D0) and after a 48 week switch (W48) from an INSTI-based regimen to the non INSTI-based regimen combining TDF/3TC/Doravirine (Delstrigo®)
Trial: NCT06540326
Drug: irinotecan liposome (II)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab
Trial: NCT06540326
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Trial: NCT06540326
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Trial: NCT05549258
Drug: Inebilizumab
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab administered intravenously (IV) over a total of 28 weeks.
Trial: NCT05400369
Drug: Sitafloxacin
RxNorm normalized name: sitafloxacin
DrugBank: Sitafloxacin (DB13261)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral administration, 50 mg tablets
Trial: NCT05400369
Drug: Moxifloxacin Hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration, 400 mg tablets
Trial: NCT05917158
Drug: RC48-ADC and JS001
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in group will receive 6 x 3 week cycles of RC48-ADC (Disitamab Vedotin) 2mg/kg in combination with JS001 (Toripalimab) 3mg/kg intravenously, followed by toripalimab (3 mg/kg) every 3 weeks for up to 1 year.
Trial: NCT06408298
Drug: Hydroxychloroquine Sulfate 400Mg Tab
RxNorm normalized name: HYDROXYCHLOROQUINE SULFATE 400MG TAB
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine sulfate tablet
Trial: NCT06029270
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06029270
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06029270
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05061368
Drug: Sildenafil Citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
Trial: NCT05260684
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 450 mg QD
Trial: NCT05260684
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45 mg BID
Trial: NCT05260684
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 960 mg BID for 28 days/cycle
Trial: NCT05260684
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 60 mg QD for 21 days/cycle
Trial: NCT05260684
Drug: Dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg BID
Trial: NCT05260684
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg QD